RxDoctor Payments Data

Jonathan Meyer, MD

Interventional Cardiology · Munster, INNPI 1285021758

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.3%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Medtronic at 41.5% of the total. 2025 is the largest year on record at $7,238, more than ten times the $254 reported in 2020.

$21,654in general payments, 2019–2025

Across 259 payments — averaging $83.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Boston Scientific$4K
  • Philips North America LLC$2K
  • Edwards Lifesciences$666
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$632
  • Abiomed$625
  • plus $5K from 30 others
$11,500in research payments, 2019–2025

Across 1 payment — averaging $11,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Penumbra, Inc.$12K

What the payments were for

  • Grants$4,00018%
  • Travel & lodging$5,43525%
  • Food & beverage$11,53953%
  • Education$6803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,654 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$242,595
Medicare patients
708
Services billed
2,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$101,326
EntrestoSacubitril/Valsartan49$48,649
JardianceEmpagliflozin22$27,394
XareltoRivaroxaban18$18,102
FarxigaDapagliflozin Propanediol15$15,377
Ranolazine ErRanolazine27$1,932
ClopidogrelClopidogrel Bisulfate193$1,616
Rosuvastatin Calcium133$1,202
Metoprolol Succinate115$1,129
Atorvastatin Calcium121$1,005
Amlodipine Besylate54$486
Bumetanide20$402
Hydralazine Hcl35$371
Furosemide118$331
Carvedilol49$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$101,32699 claims
NovartisEntresto$366$48,64949 claims
Johnson & JohnsonXarelto$68$18,10218 claims
AstraZenecaFarxiga$43$15,37715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →